EIM
KYTH

Essex Investment Management’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Essex Investment Management’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,043
Closed -$230K – 425
2013
Q3 		$230K Sell
5,043
-3,075
-38% -$92K 0.03% 326
2013
Q2 		$220K Buy
+8,118
New +$186K 0.04% 308

Other funds holding KYTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Essex Investment Management's KYTH Position: Q4 2013 in Review

Essex Investment Management sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q4 2013, closing a stake of 5,043 shares — an estimated $230K sold.

Essex Investment Management first reported a position in KYTH in Q2 2013 and held it in 2 quarters. The position peaked at $230K in Q3 2013. 92 funds tracked by Wall St. Rank hold KYTH as of Q4 2013.

  • Essex Investment Management reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q4 2013 after selling out during the quarter.
  • Essex Investment Management sold 5,043 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q4 2013, an estimated $230K.
  • Essex Investment Management first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q2 2013 and held it in 2 quarters.
  • Essex Investment Management's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $230K in Q3 2013.
  • 92 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q4 2013.

Based on Essex Investment Management's 13F filing for Q4 2013, filed 28 Jan 2014.